| 来源类型 | Testimony
|
| 规范类型 | 其他
|
| Testimony on lowering drug prices and improving Medicare |
| Benedic N. Ippolito
|
| 发表日期 | 2019-10-17
|
| 出版年 | 2019
|
| 语种 | 英语
|
| 摘要 | Chairman Neal, Ranking Member Brady, and members of the committee, thank you for the opportunity to testify on efforts to reduce prescription drug prices and improve Medicare benefits. My name is Benedic Ippolito—I am an economist and research fellow at the American Enterprise Institute.
The market for pharmaceuticals can both be extremely impressive and deeply frustrating. Without question, recent developments in this market have offered tremendous therapeutic benefits to patients. Yet, we have also seen stubbornly high prices, slow or non-existent generic drug entry, and public programs that are not working for their beneficiaries or for taxpayers. It is not surprising that Americans regularly list reducing prescription drug prices as one of their top policy priorities.
So, I am glad that this Committee, and others in both chambers, are considering this issue so seriously. In my testimony I will focus on two elements of recent proposals: Redesigning the Medicare prescription drug benefit, known as Medicare Part D, and allowing for the Secretary of Health and Human Services (HHS) to negotiate drug prices.
Read the full testimony here: |
| 标签 | drug pricing
; health insurance
; health spending
; Medicare
|
| URL | https://www.aei.org/research-products/testimony/testimony-on-lowering-drug-prices-and-improving-medicare/
|
| 来源智库 | American Enterprise Institute (United States)
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/209920
|
推荐引用方式
GB/T 7714 |
Benedic N. Ippolito. Testimony on lowering drug prices and improving Medicare. 2019.
|
|
文件名：
|
Ippolito-Testimony-1.pdf
|
|
格式：
|
Adobe PDF
|
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
